GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Archived. This submission is more than a year old. Votes and new comments are closed, and some of the advice in it may have been superseded — check the community wiki for the current version.
178
c/glp1science·posted 1 year ago by u/enzo_danquah

[Discussion] appetite is doing more work than we give it credit for

Discussion

Something I keep coming back to: appetite is doing more work than we give it credit for.

Asked a question here that I thought was stupid and got three papers back. Best thread I have been in on this site.

The GIP question, which is the most interesting unsettled thing in this field.

Dual agonism at GIP and GLP-1 receptors produces clinical results that are robust and well replicated. What is not settled is the mechanism by which the GIP arm contributes — there is a genuine scientific argument about agonism versus antagonism at that receptor, with reasonable people and real data on both sides.

It is worth sitting with that. The clinical effect is not in doubt; the explanation is. That is an ordinary state of affairs in pharmacology and it is a good corrective to the confident mechanistic stories that circulate here.

Why mechanism talk keeps misleading people, including me.

A mechanism tells you a direction. It does not tell you a magnitude, a timescale, or whether the pathway is operative at the exposures involved. "Receptor X is expressed in tissue Y" is a fact; "therefore effect Z in a person" is a hypothesis with several missing steps.

The corrective is boring and it works: ask whether the evidence is preclinical or human, ask what exposure was used, and read the limitations section before the abstract. Most of the confidently wrong posts on this board — several of them mine — skipped all three.

Ask me anything specific. Anything general I will probably get wrong.

187 up / 9 down96% upvoted24 commentsid 1x64qz4 Aug 2024

24 comments

19 in this archive, depth 5

best — the order this archive was captured in

u/gastric_emptying_gMOD27 points·1 year ago

Speculation is welcome here if it is labelled. This one has been relabelled rather than removed.

replysharereportpermalink
u/vikram_mbeki7 points·1 year ago

Glucose-dependent insulin secretion is why hypoglycaemia risk is low as monotherapy: the effect scales with glycaemia rather than acting unconditionally.

replysharereportpermalink
u/aa_analysis_andy-6 points·1 year ago

gastric emptying slows, it does not stop

replysharereportpermalink
u/not_my_main_nm1 point·1 year ago

Agreed that receptor distribution is the key to the side-effect map. It is not a mystery, it is anatomy.

replysharereportpermalink
u/dose_creep_dan1 point·1 year ago

This. Albumin binding and modification are why the half-life is what it is, and it is a design decision rather than an accident.

replysharereportpermalink
u/farid_kuipers9 points·1 year ago

receptor distribution is why the side effects are where they are

replysharereportpermalink
u/sig_figs_sammod · analytical18 points·1 year ago

Spent an evening on the receptor distribution literature and the side-effect map suddenly stopped looking random.

replysharereportpermalink
u/kavya_kravchenko15 points·1 year ago

GIP receptor biology is genuinely unsettled — there is a live argument about agonism versus antagonism at the receptor — and the clinical results are robust regardless, which is an uncomfortable and interesting position.

replysharereportpermalink
u/anders_kuusela9 points·1 year ago

Tolerance to the gastric effect develops with continued exposure while the appetite effect largely persists. That single fact explains most of the "it settles but it still works" pattern the side-effect board reports.

replysharereportpermalink
[removed]7 points·1 year ago

[removed by moderator]

replysharereportpermalink
u/enzo_danquahOP6 points·1 year ago

GIP is the arm people argue about because the biology is genuinely unsettled

replysharereportpermalink
u/bastian_eriksen0 points·1 year ago

I would not read that in vitro number across to a person. The conditions are nothing like physiological.

replysharereportpermalink
u/nurse_ish_20250 points·1 year ago

I would not read that in vitro number across to a person.

This is the concept everything else on this board is downstream of.

replysharereportpermalink
u/devils_advocate_d1 point·1 year ago·edited

Small fix — it slows gastric emptying, it does not halt it, and the distinction matters for the mechanism you are proposing.

replysharereportpermalink
u/enzo_danquahOP1 point·1 year ago

Was completely wrong about the gastric emptying story in a thread here two years ago. Someone corrected me with a citation and I have not made that mistake since.

replysharereportpermalink
u/viktor_girard5 points·1 year ago

The half-life explanation was the thing that made weekly dosing intuitive for me rather than arbitrary.

replysharereportpermalink
u/enzo_danquahOP4 points·1 year ago

The half-life explanation was the thing that made weekly dosing intuitive for me rather than arbitrary.

Disagreeing with this specific inference — that is a preclinical result being read as human pharmacology.

replysharereportpermalink
u/katrin_marchetti3 points·1 year ago

Tried to build a mental model from mechanism alone and produced a confident prediction that the trial data flatly contradicted.

replysharereportpermalink
u/milan_mensah2 points·1 year ago

Receptor expression in a tissue is necessary but not sufficient for an effect. You also need the agonist to reach it at relevant exposure, and that is where a lot of confident mechanism talk falls down.

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/glp1science

The mechanism layer: incretin physiology, receptor distribution, gastric emptying, central appetite signalling, glucagon-receptor contribution, amylin co-agonism, and the pharmacokinetics that make weekly dosing possible. Papers get cited by journal and year or they get a [needs source] reply.

50kmembers
95submissions
Oct 2023created
submissions / month, last year
Sponsored

Janoshik Analytical

Independent HPLC and mass spec. The number you get is the number they found.

janoshik.com
Sponsored

GL Biochem (Shanghai)

Custom peptides and amino acids direct from the manufacturer since 1998. ISO 9001 / cGMP. Batch COA every order.

glbiochem.net
c/glp1science rules
  1. Cite the paper: journal, year, first author. Links optional, citation mandatory.
  2. Mechanistic speculation is welcome if flaired as speculation.
  3. No extrapolating rodent data to human dosing without saying that is what you are doing.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.